{"id":20247,"date":"2026-11-19T05:15:55","date_gmt":"2026-11-19T08:15:55","guid":{"rendered":"https:\/\/rtmedical.com.br\/tmp-en-1795076154699\/"},"modified":"2026-11-19T05:16:02","modified_gmt":"2026-11-19T08:16:02","slug":"psma-pet-upstaging-patron-trial","status":"publish","type":"post","link":"https:\/\/rtmedical.com.br\/en\/psma-pet-upstaging-patron-trial\/","title":{"rendered":"PSMA PET Upstages Nearly 4 in 10 in PATRON Prostate Trial"},"content":{"rendered":"<p>F-18 PSMA PET upstaged nearly four in 10 men with high-risk or biochemically recurrent prostate cancer in a secondary analysis of PATRON, a Canadian phase III trial that randomized 796 patients before radiotherapy or surgery. The data will be presented on December 2 at RSNA 2026 and have not yet appeared in a journal; whether this stage migration improves cancer control will only be known with follow-up.<\/p>\n<p>Sympascho Young, MD, of the University of Calgary, presents the work in session W6-SSNMMI06-8. The analysis covers the 390 men in the PET arm, split into two groups that radiation oncology departments see every week: newly diagnosed high-risk disease and a rising PSA after radical prostatectomy.<\/p>\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" class=\"alignright lazyload\" data-src=\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/11\/psma-pet-detection-psa-patron.png\" alt=\"Bar chart: in the PATRON trial, PSMA PET new-lesion detection rose from 32% to 61% in high-risk prostate cancer and from 33% to 85% in recurrence after prostatectomy as PSA increased\" width=\"640\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1200px; --smush-placeholder-aspect-ratio: 1200\/630;\"><figcaption>PSMA PET new-lesion detection by PSA band in the PATRON trial. Preliminary data from the RSNA 2026 abstract. Chart: RT Medical.<\/figcaption><\/figure>\n<h2>How the PATRON trial was designed<\/h2>\n<p>PATRON (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04557501\" target=\"_blank\" rel=\"noopener\">NCT04557501<\/a>) is a pragmatic trial led by the Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM). It opened in January 2021 at centers across Canada, and the abstract reports 19 participating institutions. The protocol, published in BMC Cancer in 2022, enrolled two populations: untreated men with a CAPRA score of 6 to 10 or clinically node-positive (cN1) disease who were planned for radiotherapy or prostatectomy with lymph node dissection, and men with biochemical failure after radical prostatectomy (PSA above 0.1 ng\/mL) referred for salvage radiotherapy.<\/p>\n<p>Before randomization, each team set a treatment plan based on conventional staging, meaning abdominopelvic CT and a bone scan. Half the patients followed that plan. The other half also underwent PSMA PET with one of two F-18 tracers, DCFPyL or PSMA-1007, and had their therapy intensified according to the findings after local and central reads. De-intensification is not allowed: a negative scan does not remove pelvic nodal radiotherapy that was already planned, for example. The primary endpoint is five-year failure-free survival, a composite of biochemical failure, local or regional failure, distant metastasis and death, with primary completion estimated for 2029. Lantheus Medical Imaging, which makes DCFPyL, is listed among the trial collaborators.<\/p>\n<h2>Nodes, oligometastases and the weight of PSA<\/h2>\n<p>In the high-risk group (203 men), PET found new lesions in 39% and upstaged 39%. Most of the shift came from the pelvis: 22% were reclassified as N1 with regional nodal disease. Another 13% had oligometastases, defined as five or fewer sites, 2.5% moved to T3 with extraprostatic extension and 2.5% had polymetastatic disease. The chance of finding a new lesion climbed with PSA, from 32% below 20 ng\/mL to 61% at 40 ng\/mL or above.<\/p>\n<p>In the post-prostatectomy recurrence group (187 men), detection reached 51% and 38% were upstaged. The PSA gradient was steeper here: 33% when PSA was below 0.2 ng\/mL and 85% at 1.0 ng\/mL or higher. In multivariate analysis, International Society of Urological Pathology (ISUP) Grade Group 5 and PSA level independently predicted new lesion detection and stage migration in both groups.<\/p>\n<p>The investigators note that the effect of PSMA PET on treatment decisions and outcomes in a prospective randomized setting is less established than its diagnostic accuracy. \u201cThe impact of PSMA-PET-guided therapy intensification on patient outcomes is pending follow-up,\u201d the group wrote.<\/p>\n<h2>Why PSA level and ISUP grade matter<\/h2>\n<p>Prostate-specific membrane antigen is a protein heavily expressed on the surface of most prostate adenocarcinoma cells. The tracer binds to it, revealing deposits that CT misses because it relies on node size and that a bone scan misses because it relies on the bone\u2019s reaction to tumor. A higher PSA usually reflects a larger tumor burden, and ISUP Grade Group 5, the most aggressive histologic pattern, is linked to earlier spread.<\/p>\n<p>The protocol chose F-18 for practical reasons: a half-life of about 110 minutes versus 68 for gallium-68, and several doses per cyclotron run that can be shipped to sites without a radiopharmacy. The same test is moving into other steps of the pathway, from <a href=\"https:\/\/rtmedical.com.br\/en\/psma-pet-mri-pre-biopsy-fda\/\">PSMA PET combined with MRI before biopsy<\/a> to <a href=\"https:\/\/rtmedical.com.br\/en\/psma-pet-biopsy-negative-mri\/\">PSMA PET\/CT-guided biopsy after a negative MRI<\/a>.<\/p>\n<h2>What changes in radiotherapy planning<\/h2>\n<p>For treatment planners, PATRON\u2019s percentages translate into changes in target volumes and dose. In the experimental arm, every lesion rated probably or definitely malignant on PET must be included in the definitive plan. New pelvic nodes are irradiated, with escalated dose objectives that the protocol lists in EQD2, the equivalent dose in 2 Gy fractions, using an alpha\/beta ratio of 1.4. Up to five ablatable metastases receive stereotactic ablative radiotherapy (SABR) or surgery on top of the planned treatment. Widespread disease shifts care to continuous hormone therapy, with additional systemic therapy at the investigator\u2019s discretion, and ablation of metastases is not permitted.<\/p>\n<p>In practice that means redrawing pelvic volumes and adding boosts to PET-positive nodes, which depends on careful registration between PET and the planning CT and on revisiting <a href=\"https:\/\/rtmedical.com.br\/en\/prostate-ctv-imrt\/\">CTV delineation for prostate IMRT<\/a>. The protocol sets rectum, bladder and bowel dose limits for conventional and hypofractionated schedules of 5 to 22 fractions, which overlaps with the <a href=\"https:\/\/rtmedical.com.br\/en\/astro-prostate-hypofractionation-guideline\/\">updated ASTRO prostate hypofractionation guideline<\/a>. For the 13% with oligometastases, the path is metastasis-directed therapy, an approach other trials are already combining with radioligands, such as the study of <a href=\"https:\/\/rtmedical.com.br\/en\/lutetium-177-sbrt-prostate-lunar\/\">lutetium-177 before SBRT<\/a>.<\/p>\n<p>In the salvage setting, 33% detection at a PSA below 0.2 ng\/mL shows that the scan can localize disease outside the prostate bed early. The reverse reading matters too: at low PSA, a negative PET does not rule out microscopic disease in the bed. In Brazil and the rest of Latin America, where access to PSMA PET varies by region and payer, simple predictors such as PSA and ISUP grade could help prioritize patients most likely to have their management changed. That is an editorial inference, not a recommendation from the trial.<\/p>\n<h2>Limitations and what to watch in PATRON<\/h2>\n<p>The figures come from a conference abstract and have not been through full-paper peer review. Confidence intervals, intermediate PSA bands, agreement between local and central reads and the share of lesions confirmed by histology were not reported. The analysis describes only the PET arm, so it does not compare outcomes. Detection and upstaging are not the same as clinical benefit: stage migration can create the Will Rogers effect, in which both groups appear to do better simply because patients moved between categories.<\/p>\n<p>The phase 2 predecessor shows why caution is warranted. PSMAgRT, <a href=\"https:\/\/doi.org\/10.1016\/j.eururo.2026.09.017\" target=\"_blank\" rel=\"noopener\">published in European Urology in October<\/a>, randomized 262 patients and, after a median 66 months, missed its primary endpoint: five-year failure-free survival was 66% with PSMA-guided radiotherapy versus 62% in controls. Freedom from biochemical progression favored PET (72% vs. 65%), with a clearer signal in the high-risk and post-prostatectomy strata, the very populations PATRON enrolled. PATRON is powered to detect a hazard ratio of 0.68 for failure-free survival. Until that result arrives, PSA stays at the center of decisions, from <a href=\"https:\/\/rtmedical.com.br\/en\/acs-prostate-screening-psa\/\">the ACS PSA screening recommendation<\/a> to the choice of PET for staging.<\/p>\n<p><strong>Source:<\/strong> <a href=\"https:\/\/www.auntminnie.com\/resources\/conference\/rsna\/2026\/molecular-imaging-preview\/article\/16541883\/psmapet-upstages-men-with-highrisk-or-recurrent-prostate-cancer\" target=\"_blank\" rel=\"noopener\">AuntMinnie \u2014 PSMA-PET upstages men with high-risk or recurrent prostate cancer<\/a>. Protocol: <a href=\"https:\/\/doi.org\/10.1186\/s12885-022-09283-z\" target=\"_blank\" rel=\"noopener\">M\u00e9nard C et al., BMC Cancer, 2022<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the PATRON trial, F-18 PSMA PET upstaged 39% of high-risk and 38% of recurrent prostate cancer cases. See what it means for radiotherapy.<\/p>\n","protected":false},"author":5,"featured_media":20206,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0,"_rt_cluster":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[100,99],"tags":[],"class_list":["post-20247","post","type-post","status-publish","format-standard","has-post-thumbnail","category-radiology","category-radiotherapy"],"aioseo_notices":[],"rt_seo":{"title":"","description":"In the PATRON trial, F-18 PSMA PET upstaged 39% of high-risk and 38% of recurrent prostate cancer cases. See what it means for radiotherapy.","canonical":"","og_image":"","robots":"index,follow","schema_type":"Article","include_in_llms":true,"llms_label":"PSMA PET in the PATRON trial (RSNA 2026)","llms_summary":"Secondary analysis of the Canadian phase III PATRON trial (NCT04557501), RSNA 2026 abstract: F-18 PSMA PET found new lesions in 39% of high-risk men and 51% with post-prostatectomy recurrence, upstaging about 4 in 10; detection rises with PSA and ISUP Grade Group 5. Outcome impact still pending.","faq_items":[],"video":[],"gtin":"","mpn":"","brand":"","aggregate_rating":[]},"_links":{"self":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20247\/"}],"collection":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/"}],"about":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/types\/post\/"}],"author":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/users\/5\/"}],"replies":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/comments\/?post=20247"}],"version-history":[{"count":1,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20247\/revisions\/"}],"predecessor-version":[{"id":20249,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20247\/revisions\/20249\/"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/20206\/"}],"wp:attachment":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/?parent=20247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/categories\/?post=20247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/tags\/?post=20247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}